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Abstract
Background: Epstein-Barr virus (EBV) DNA load monitoring is known to be useful for the
diagnosis and monitoring of EBV-associated diseases. The aim of this study is to compare the
performance of two real-time PCR assays for EBV DNA: a commercial kit as the Q-EBV Real-Time
System (Q-EBV PCR, Amplimedical, Turin, Italy) and an in-house assay (EBV RQ-PCR).
Results: The range of linearity and the degree of precision of the two assays were similar. The
clinical sensitivity of Q-EBV PCR was higher for reference samples containing less than 1,000 EBV
DNA copies/ml. The absolute quantitative results of the two methods were statistically correlated
(R2 = 0.7789; p < 0.0001), with the systematic overestimation by EBV RQ-PCR possibly linked to
different amplification efficiency in calibration standards.
Conclusion: Both the commercial and the in-house assay may be appropriate for clinical use, but
common standards are advisable for comparable absolute values, as these would improve the
clinical utility of EBV DNA load measurement.
Background
Epstein-Barr virus (EBV) is a ubiquitous human B-lym-
photropic herpesvirus that infects more than 90% of the
world's population and establishes a lifelong (usually
asymptomatic) infection in its host. It has been estimated
that the number of EBV-infected B cells is controlled in
healthy individuals by EBV-specific immunity [1]. Never-
theless, EBV is the causative agent of infectious mononu-
cleosis and is associated with several malignant
proliferative disorders such as Burkitt's lymphoma, Hodg-
kin's lymphoma, some B- and T-cell non-Hodgkin's lym-
phomas, and nasopharyngeal and gastric carcinoma [2-5].
In immunocompromised subjects, active EBV infection is
a strong risk factor for the development of post-transplant
lymphoproliferative disease (PTLD) and AIDS-related
lymphoma [6].
Quantitative molecular assays for the assessment of viral
load have helped to describe and monitor EBV-related dis-
eases. Although highly sensitive, however, conventional
quantitative PCR is rather laborious and time-consuming.
In contrast, real-time amplification technology can over-
come these difficulties. A range of different assay formats
and protocols involving TaqMan probes [7,8] and fluores-
cence resonance energy transfer probes [9-12] have been
reported and various in-house and commercial assays for
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EBV load measurement are available [3,7-10,13,14].
However, the considerable differences in EBV load
detected by quantitative assays [15] constitute an
unsolved problem. This study compares the performance
of two real-time PCR assays for EBV DNA: a commercial
kit (Q-EBV PCR; Amplimedical, Turin, Italy) and an in-
house assay (EBV RQ-PCR) [13].
Results
In order to evaluate the dynamic range of the assays, 10
serial five-fold dilutions of culture supernatant derived
from an EBV-positive cell line were tested in triplicate by
both methods. These were prepared since high-titre refer-
ence material was not available. For each method, linear
results were obtained up to 3-log dilution, whereas the
three further five-fold dilutions showed comparable
quantitative results. Only 1–2 out of 3 replicates were
detected in the last two possible dilutions, while 10-5 dilu-
tion was negative in both assays. Altogether, the in-house
assay (EBV RQ-PCR) showed a remarkable overestimation
(on average, about 2 log) of quantitative results, as com-
pared to the commercial assay (Q-EBV PCR) (Figure 1). To
establish the level of precision, inter- and intra-assay vari-
ability was determined by amplifying replicates of three
dilutions of EBV-positive culture supernatant using the
same DNA as a sample in both methods (Table 1). Intra-
assay variability of the Q-EBV PCR and EBV RQ-PCR
methods was determined by amplifying all samples in
quadruplicate, whereas inter-assay variability was deter-
mined by amplifying the three dilutions in triplicate in
four independent experiments. Overall, the last dilution
reached in both methods the highest coefficient of varia-
tion and linearity lack for values near or just below the
cut-off level. Moreover, the in-house EBV RQ-PCR reached
a slightly higher intra-assay precision and lower inter-
assay precision, compared to the commercial assay.
The accuracy of the two methods was evaluated using a
Quality Control for Molecular Diagnosis (QCMD) EBV
2003 proficiency panel. Aliquots of QCMD samples were
extracted and aliquots of the DNA samples were analysed
at the same time by each assay, avoiding repeated freeze-
thaw cycles. Both methods correctly classified the only
negative sample (QC2) and all the samples (QC1, QC3,
QC5 and QC6) containing more than 1,000 copies/ml, as
determined by EM. Only Q-EBV-PCR detected three more
samples with a viral load of 100–1,000 copies/ml (QC4,
QC7 and QC8), though not all replicates were positive
(Table 2). Quantitative results indicated an overestima-
tion by EBV RQ-PCR (mean = 1.28 log) and an underesti-
mation by Q-EBV-PCR (mean = 0.54 log), as compared to
EM quantification.
Of 199 consecutive plasma samples received by our labo-
ratory for EBV DNA quantification, 17 were positive and
182 negative by both methods. All the samples were mon-
itored for the presence of inhibitors by adding internal
positive controls, beta globin and actin DNA, and no neg-
ative results or partial amplification were observed. All the
50 plasma samples from healthy blood donors were neg-
ative in both assays. The mean copy numbers for the 17
positive plasma samples was respectively 23,583 copies/
ml (for Q-EBV-PCR) and 360,256 copies/ml (for EBV RQ-
PCR) (p < 0.0001). Considering all the 31 samples posi-
tive to both tests and including the QCMD EBV panel
samples and serial dilutions of culture supernatant
obtained from immortalized clinical specimen lym-
phocytes, the results of the two methods were statistically
correlated (R2 = 0.7789; p < 0.0001) (Figure 2). A system-
atic difference was noted by plotting the mean value of
each positive sample tested by both assays against the dif-
ference between the results of the two methods (Figure 3),
with about 1.9 log mean overestimation by EBV RQ-PCR.
The different levels of circulating EBV DNA measured by
each assay might be due to a difference in PCR efficiency.
PCR efficiency was calculated by the equation E = [10-1/
slope of the standard curve]-1. The mean percentage of PCR effi-
ciency, based on 5 consecutive experiments measuring
inter- and intra-assay variability, was 96.92% for Q-EBV
PCR and 90.41% for EBV RQ-PCR. One of the variables
possibly affecting PCR efficiency is the source of DNA
used as a standard for quantification (plasmid DNA for Q-
EBV-PCR or genomic DNA for EBV RQ-PCR) [12]. To test
this hypothesis, samples of Namalwa cellular DNA used
in the standard curve of the in-house method were ampli-
fied in the commercial assay: EBV DNA values were on
average 17.7 fold lower than expected (range 14–20). By
contrast, when Namalwa DNA dilutions were used as a
standard in the same experiment, PCR efficiency was
about 8% lower (84.6% versus 92.3%). The amplification
of the plasmid standards enclosed in the Q-EBV PCR kit
yielded copy numbers 14.4 fold higher than the expected
average (range 11.3–18).
Discussion
The quantification of EBV DNA load is useful for detecting
viral reactivation, which increases the risk of PTLD in
immunosuppressed patients [16,17], and monitoring
antiviral therapy. In addition, recent studies suggest that
EBV DNA fragments are released from tumour cells in
nasopharyngeal carcinoma and EBV-positive lymphomas
[18-22]. In such cases, the EBV DNA load may be used as
a surrogate disease activity marker with potential applica-
tions in clinical monitoring and prognostication. In order
to determine the clinical significance of an EBV load, it
might be better to monitor viral load dynamics in patients
by quantification of EBV load in peripheral mononuclear
cells (PBMCs), though EBV DNA is detectable during
active infection for a longer period in whole blood than inBMC Microbiology 2007, 7:22 http://www.biomedcentral.com/1471-2180/7/22
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plasma [23,24]. However, the real-time PCR protocol
used in these assays is preferable for the quantification of
viral load in plasma or liquor.
Today a wide variety of quantitative PCR assays are avail-
able for EBV DNA quantification, including quantitative-
competitive PCR and real-time PCR (TaqMan PCR and
LightCycler PCR) [3,8-10,12-14]. They are faster than con-
ventional quantitative PCR and employ a close-tube sys-
tem that eliminates the need for post-PCR analysis, thus
reducing the risk of contamination. Although real-time
PCR assays are known to be of excellent diagnostic value
in certain clinical settings, interlaboratory standardization
of EBV DNA load monitoring has yet to be achieved [15].
We compared the performance of two real-time PCR
assays for EBV DNA quantification in plasma, one of
which is commercial (Q-EBV PCR) and the other in-house
(EBV RQ-PCR). False negative results, due to the presence
of inhibitors, did not occur and none of the samples
inhibited amplification of the internal positive control in
either of the real-time PCR assays. These results confirm
that the method used for DNA extraction does provide an
inhibitor-free target for quantitative assessment by PCR.
Several factors have been linked to variation in PCR
results, including PCR reagents, primer stability and spe-
cificity, and PCR product size [25]. The choice of target
region for amplification is known to influence signifi-
cantly the results of quantitative EBV DNA assays. One of
the most widely used PCR targets, the BamHI-W region,
occurs in multiple repeats which can vary considerably
across naturally occurring EBV isolates. For this reason,
the EBV DNA load can be up to 5-fold higher when
Table 1: Intra- and inter-assay reproducibility of EBV RQ-PCR in-house assay and Q-EBV PCR quantification kit tested on serial 
dilutions of culture supernatant. 
Comparison Method Dilution Mean EBV DNA load (copies/reaction) ST. DEV. CV (%)
INTRA-ASSAY EBV RQ-PCR Und. 19511 2557 13
1:10 5403 420 8
1:100 2055 605 29
Q-EBV PCR Und. 1852 312 17
1:10 75 12 16
1:100 12 4 36
INTER-ASSAY EBV RQ-PCR Und. 43774 16467 28
1:10 2406 544 35
1:100 1116 618 37
Q-EBV PCR Und. 4363 998 21
1:10 241 84 24
1:100 22 7 31
ST. DEV.: Standard Deviation; CV: Coefficient of Variation; Und.: undiluted.
Correlation of EBV DNA load between EBV RQ-PCR (in-house assay: blank squares; R2: 0.999) quantification assay and Q-EBV  PCR (commercial assay: blank triangles; R2: 0.999) Figure 1
Correlation of EBV DNA load between EBV RQ-PCR (in-house assay: blank squares; R2: 0.999) quantification assay and Q-EBV 
PCR (commercial assay: blank triangles; R2: 0.999). The table lists Ct values and log copies. Copies were obtained by both real-
time methods. Ct: Cycle threshold # = 1/3 replicates; * = 2/3 replicates.
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BamHI-W primers are used, as compared to primers
located in single-copy EBV genes [22]. This observation,
however, does not account for the discrepancies observed
in the present study, as both assays amplify the single-
copy EBNA-1 gene.
Real-time PCR quantification relies on the assumption
that amplification efficiencies are the same for patient
samples and in the standard used for calibration. Low
amplification efficiency in patient samples, compared to
the calibrator, lead to underestimation of the DNA con-
tent in samples [26]. Alternatively, it can be argued that
the decreased PCR efficiency of standards may lead to
overestimation of DNA samples. The DNA standard
source used to build a calibration curve appears to be cru-
cial in determining the final outcome of quantification
[19,22]. Indeed, we observed a lower rate of efficiency in
the in-house assay, using a genomic standard, as com-
pared to the commercial assay, which employs a plasmid
standard. The influence of calibrator DNA on the assay's
quantitative results is supported by the observation that
when genomic DNA was used as a standard in the com-
mercial assay, amplification efficiency was lower, and
higher EBV DNA values were measured on plasmid sam-
ples containing known amounts of EBV DNA.
Conclusion
Our results suggest that commercial and in-house assays
for the quantification of EBV DNA are both appropriate
for clinical use because they perform similarly in analyti-
cal terms and generate correlated quantitative results. The
use of common standards would help to achieve compa-
rable absolute values, thus limiting the high degree of var-
iability in EBV DNA load shown by various assays [12,27]
and improving the diagnostic significance of real-time
EBV copy number quantification.
Given the high coefficients of variation involved, it would
also help to specify the confidence interval in reported
results (as an estimate of uncertainty), so that viral load
fluctuations are not misinterpreted as clinically significant
data.
Table 2: QCMD EBV 2003 panel results by EBV RQ-PCR and Q-EBV PCR quantification assay.
QCMD sample Q-EBV-PCR EBV RQ-PCR
(copies/ml) (Ct) (copies/ml) (Ct)
EM copies/ml
QC1-10000 2350 33.26 99424 35.35
QC2-1 1 40.00 1 40.00
QC3-2500 220 37.01 19548 37.90
QC4-500 265 36.90 § 1 40.00
QC5-5000 1535 33.89 94985 35.48
QC6-1000 205 36.85 §§ 34737 37.36
QC7-100 81.25 38.20 § 1 40.00
QC8-250 134.4 37.46 § 1 39.50
EM: electron microscope; Ct: Cycle threshold
§= 1/3 replicates; §§ = 2/3 replicates
Correlation of EBV DNA loads by EBV RQ-PCR (in-house  PCR) and Q-EBV PCR in 31 samples positive in both assays Figure 2
Correlation of EBV DNA loads by EBV RQ-PCR (in-house 
PCR) and Q-EBV PCR in 31 samples positive in both assays.
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Methods
Samples
This study included a total of 199 consecutive plasma
samples received by the Microbiology Laboratory of
Brescia Hospital (Spedali Civili) between June and
December 2005 for EBV viral load determination by real-
time PCR.
The sensitivity, linear range and precision of the real-time
assays were compared using DNA extracted from five-fold
dilutions of EBV-positive culture supernatant (B-95.8 cell
line). As negative controls for EBV RQ-PCR, we tested 6
supernatants of viral cultures from Herpes Simplex Virus
type 1 (n = 4) and type 2 (n = 2) seropositive patients, who
were also positive by PCR hybridized on Gen-ETI-K™
DEIA (DiaSorin, Vercelli, Italy), and 50 plasma samples
from healthy blood donors. The B-95.8 EBV-positive cell
line and 6 EBV positive cell lines, immortalized in our lab-
oratory from patients with Mycosis Fungoides [28] served
as positive controls for EBV-specific amplification.
In order to assess the accuracy of molecular amplification,
samples from the Quality Control for Molecular Diagnos-
tic (QCMD) 2003 Epstein-Barr virus proficiency panel
were analyzed in triplicate. The panel consisted of 7 fro-
zen plasma samples containing different concentrations
of electron microscope (EM)-quantified EBV samples and
one EBV-negative plasma sample.
B-95.8 cell line
The marmoset blood leukocytes B-95.8 EBV transformed
cell line is a continuous line that releases high titres of
transforming EBV (ATCC CRL 1612). The DNA was
extracted from the culture supernatant using QIAamp
DNA Mini (Qiagen, Hilden, Germany) as reported by the
manufacturer and the DNA serial dilution was made with
sterile water.
Commercial assay (Q-EBV PCR)
DNA was extracted by QIAamp DNA Mini (Qiagen,
Hilden, Germany) using the "Blood and body fluid proto-
Differences from the mean for all positive samples by EBV RQ-PCR and Q-EBV PCR quantification assays Figure 3
Differences from the mean for all positive samples by EBV RQ-PCR and Q-EBV PCR quantification assays.
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col" as recommended in the manufacturer's instructions,
starting from 200 μl of plasma. It was eluted in a final vol-
ume of 50 ul. Q-EBV PCR for a highly conserved region of
gene EBNA-1 was performed in 25 μl on 5 μl DNA,
according to the manufacturer's instructions, using Q-EBV
AmpliMASTER, Q-EBV Amplimix containing the EBNA-1
primer set and Q-EBV AmpliPROBE (Amplimedical). EBV
DNA was quantified by Q-EBV AmpliSTANDARD, con-
sisting of serial dilutions of a plasmid containing the tar-
get amplification region as multiple tubes of prediluted
plasmid, ranging in concentration from 1.0 × 105 to 1.0 ×
102 copies/reaction, as determined by the manufacturer
spectrophotometric reading. As reported in the manufac-
turer's package insert, the lower detection limit is 10 cop-
ies/ml. The reactions were carried out on an ABI PRISM
7300 Analytical PCR System (Applied Biosystems, Foster
City, CA), according to the manufacturer's instructions.
The PCR cycle protocol consist of 2 min at 50°C, 10 min
at 95°C, and 45 two-step cycles of 15 sec each at 95°C and
of 1 min at 60°C. This method allows linear quantifica-
tion of 101 to 106 DNA copies per reaction, as stated by the
manufacturer. To establish the concentration of EBV DNA
copies per ml, the readings were multiplied by 62.5,
assuming an 80% mean efficiency of DNA extraction, as
suggested by the manufacturer.
Appropriate positive and negative controls were included
in all the experiments. As a control for PCR inhibitors and
amplification quality, β-globin DNA (CPE-DNA, Ampli-
medical) was added to each sample before the extraction
step, according to the manufacturer's instructions, and
amplified with β-globin primers in the same reaction mix
as EBV in multiplex PCR.
In-house assay (EBV RQ-PCR)
DNA was extracted as reported above. The real-time assay
was performed as described by Wagner et al. [2001], with
minor adjustments. The BAM HI-K region, encoding for
EBNA-1 gene, was chosen as an amplification target [13].
Briefly, 5 μl of DNA were amplified with TaqMan Univer-
sal Master Mix (Applied Biosystems, Foster City, CA),
adjusted to a volume of 25 μl with 50 nM of forward
primer (5'-CCGGTGTGTTCGTATATGGAG-3'), 300 nM of
reverse primer (5'-GGGAGACGACTCAATGGTGTA-3'),
200 nM of probe (5'VIC-TGCCCTTGCTATTCCACAAT-
GTCGTCTT-TAMRA3') and distilled water. Primers and
probe were synthesized by MWG Biotech S.r.l. (Ebersberg,
Germany). Each reaction consisted of 2 min at 50°C, 10
min at 95°C, and 40 two-step cycles of 15 sec each at
95°C and of 1 min at 60°C. For quantification of EBV
DNA, serial 10-fold dilutions of DNA extracted from
Namalwa cells were used as a standard, ranging in concen-
tration from 1.0 × 105 to 1.0 × 102 copies/reaction, as
quantified by spectrophotometry, diluted in sterile water
and used directly in PCR. Since Namalwa cells contain
two integrated EBV copies per cellular genome, it was pos-
sible to calculate the number of target EBV genomes from
the cellular Namalwa DNA amount using the equation:
33 pg of Namalwa DNA contain 10 EBV genome copies.
Each reaction was performed using an ABI PRISM 7700
analytical PCR system (SDS version 1.7) (Applied Biosys-
tems) with the amplification and detection conditions set
by the instrument. The detection limit of the assay is 3.3
pg of Namalwa DNA, equivalent to 1 EBV genome per
reaction [13]. The EBV DNA load per ml was calculated as
described for the Q-EBV PCR assay. Positive and negative
controls were included in all the experiments and each
sample was run in duplicate for each PCR. As a control for
PCR inhibitors, β-actin amplification (TaqMan Beta-Actin
Detection Reagents, Applied Biosystems) was performed
in multiplex with EBV, according to the manufacturer's
guidelines.
Statistics
The differences in viral load values were calculated using
a Wilcoxon W test for paired samples. Intra- and inter-
assay variations were evaluated by descriptive statistics.
The relationship between viral loads was assessed by
regression analysis. Bland and Altman's method was
adopted to analyze the agreement between viral load
measurements of the positive samples. Statistical data was
processed using MedCalc 8.1.1.0 software, with a p value
< 0.05 judged to be statistically significant.
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